Group: Board of Directors

John Taylor

John is Co-Founder, President and CEO of Aceragen and a member of the board of directors. Prior to Aceragen, John co-founded and was President and CEO of Spyryx Biosciences, a company he spun out of UNC-Chapel Hill to develop inhaled peptides for cystic fibrosis. Under his leadership Spyryx raised over $23 million in venture capital

Ron Wooten

As founding Managing Partner, Mr. Wooten has extensive healthcare and investing experience. His responsibilities include NovaQuest Capital’s overall oversight, investment policy, investor relations, and the day-to-day management of NovaQuest Capital and its investment platform. He is also a member of the Private Equity and Product Finance investment committees. Over a ten-year period during which NovaQuest

Atul Chopra

Atul is a Physician-Scientist and Medical Geneticist specializing in rare genetic disorders of metabolism and energy balance. These disorders typically have a genetic cause such as a single gene mutation or a larger deletion/duplication affecting many genes together. An example of his work is the discovery of asprosin, a hormone that controls appetite and glucose

Dan Salain

Dan has 28 years of global pharmaceutical experience in manufacturing, supply chain management, strategic sourcing, distribution, quality, operations and business development. During his career, he participated in the successful launch and introduction of over 30 global products including Zenpep®, Lamictal®, Amrix®, Canasa® and Metadate CD®. Prior to joining Aceragen, he served as COO at Graybug

Andy Jordan

My career started in public accounting where I rose to the level of partner at KPMG. Having worked with many entrepreneurs, I sought to do the same and left KPMG in 1993 to help start Guilford Pharmaceuticals, a biotech company located in Baltimore, MD. At Guilford, I helped take Guilford through an IPO and over